Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

Vanderbilt University presents new muscarinic M4 receptor antagonists

Aug. 29, 2019

Aptinyx discovers NMDA receptor modulators

Aug. 29, 2019

European Commission approves Soliris for neuromyelitis optica spectrum disorder

Aug. 28, 2019

FDA approves Nourianz for Parkinson's disease

Aug. 28, 2019

IRLAB to prioritize L-dopa-induced dyskinesia indication in development of IRL-790

Aug. 28, 2019

Lilly discovers TRPA1 antagonists

Aug. 28, 2019

Conditional deletion of Talpid3 produces mouse model of Joubert syndrome

Aug. 28, 2019

FDA clears IND for long-acting injectable antipsychotic based on MedinCell technology

Aug. 28, 2019

New lysosomal acid glucosylceramidase inhibitors identified at Takeda

Aug. 27, 2019

Esteve Pharmaceuticals describes dual CACNA2D1/mu opioid receptor ligands

Aug. 27, 2019

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 22, 2026.
‘Detargeted’ targeted gene therapy improves activity in Pompe
BioWorld
A new strategy aims to improve gene therapy for Pompe disease by optimizing both the genetic component that restores the function of a deficient lysosomal enzyme...
Roche reports new TREM2 agonists
BioWorld Science
F. Hoffmann-la Roche Ltd. and Hoffmann-La Roche Inc. have identified new triggering receptor expressed on myeloid cells 2 (TREM2) agonists potentially useful for...
Genescience presents STAT6 degrader for atopic dermatitis
BioWorld Science
Genescience Pharmaceutical Co. Ltd. has presented data on a new STAT6 PROTAC degrader – GenSciP166 – which selectively targets STAT6 for proteasomal degradation....
Unmasking the X: EPAC2 shifts the fragile X landscape
BioWorld
Researchers at UCLA have shown that divergent neuronal signaling in fragile X mice converges on EPAC2, a druggable target whose inhibition restores circuit...